OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
John V. Heymach(The University of Texas MD Anderson Cancer Center), Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), Jacqulyne Robichaux(The University of Texas MD Anderson Cancer Center), B. Carter(The University of Texas MD Anderson Cancer Center), Ami Patel(The University of Texas MD Anderson Cancer Center), Mehmet Altan(The University of Texas MD Anderson Cancer Center), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Frank V. Fossella(The University of Texas MD Anderson Cancer Center), George R. Simon(The University of Texas MD Anderson Cancer Center), Vincent K. Lam(The University of Texas MD Anderson Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Jonathan M. Kurie(The University of Texas MD Anderson Cancer Center), Frank E. Mott(The University of Texas MD Anderson Cancer Center), David W. Jenkins(The University of Texas MD Anderson Cancer Center), David H. Mack(The University of Texas MD Anderson Cancer Center), Lei Feng(The University of Texas MD Anderson Cancer Center), Brent Roeck(Spectrum Pharmaceuticals (United States)), Zane Yang(Spectrum Pharmaceuticals (United States)), V. Papadimitrakopoulou(The University of Texas MD Anderson Cancer Center), Yasir Y. Elamin(The University of Texas MD Anderson Cancer Center)
Cited by 86Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis